XCancer

Phase 1/2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Description:

Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells. Objective: To test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC.

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases

Phase:

Phase 1/2

Contacts:

Joanna Klubo-Gwiezdzinska, M.D.

joanna.klubo-gwiezdzinska@nih.gov

(301) 496-5052

Padmasree Veeraraghavan, R.N.

padmasree.veeraraghavan@nih.gov

(301) 451-7710

Government Study Link:

NCT06991738 - Click here to see study on

ClinicalTrials.gov

Lu 177-DOTA-EB-TATE

Isotope(s):
Target(s):
  • SSTR+
Ligand Class: Small Molecules
Chelator: DOTA